FMP
Nanobiotix S.A.
NBTX
NASDAQ
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
3.15 USD
-0.15 (-4.76%)
Latest NBTX News
Alex Lavoie
Apr 2, 2025
Nanobiotix's Financial and Developmental Update: A Glimpse into the Future
Nanobiotix, listed as NASDAQ:NBTX, is a biotechnology company specializing in nanoparticle-based treatments for cancer. The company focuses on developing innovative therapies, particularly in oncology, targeting diseases like head and neck cancer and lung cancer. Despite its promising pipeline, NBTX faces financial challenges, as reflected in its recent earnings report. On April 2, 2025, NBTX reported an earnings per share (EPS) of -$0.58, aligning with the estimated EPS. The company's revenue ...
GlobeNewsWire
May 28, 2024
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncol...
PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of updated data from the completed dose escalation part and first data from the ongoing expansion part of Study 1100, a US Phase 1 study evaluating NBTXR3 follow...
GlobeNewsWire
May 23, 2024
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event.
Seeking Alpha
May 22, 2024
Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Chang - Leerink Partners Lucy Codrington - Jefferies Chiara Montironi - Van Lanschot Kempen Swayampakula Ramakanth - H.C.
GlobeNewsWire
May 15, 2024
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST
Seeking Alpha
Apr 27, 2024
Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2023 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Dylan Drakes - Leerink Partners Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C.
GlobeNewsWire
Apr 17, 2024
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST
GlobeNewsWire
Mar 6, 2024
Nanobiotix to Present at Upcoming Investor Conferences in March
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event.
GlobeNewsWire
Jan 31, 2024
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on ...
Seeking Alpha
Nov 14, 2023
Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Craig West - Senior Vice President of Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
